Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 2,347 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 2,347 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $9.47, for a total transaction of $22,226.09. Following the completion of the transaction, the executive vice president now directly owns 61,370 shares of the company’s stock, valued at $581,173.90. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Verneuil Vanina De also recently made the following trade(s):

• On Friday, November 1st, Verneuil Vanina De sold 1,403 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.20, for a total value of $10,101.60.

Vir Biotechnology Trading Down 3.9 %

NASDAQ VIR opened at $9.77 on Friday. The firm’s 50 day moving average is $7.83 and its 200-day moving average is $8.90. Vir Biotechnology, Inc. has a 12-month low of $7.12 and a 12-month high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $2.38 million during the quarter, compared to analyst estimates of $5.54 million. During the same quarter in the previous year, the firm posted ($1.22) earnings per share. The firm’s quarterly revenue was down 9.8% on a year-over-year basis. As a group, research analysts predict that Vir Biotechnology, Inc. will post -3.86 EPS for the current fiscal year.

Institutional Trading of Vir Biotechnology

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Blue Trust Inc. boosted its position in Vir Biotechnology by 143.5% during the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after purchasing an additional 2,351 shares during the last quarter. Innealta Capital LLC bought a new stake in Vir Biotechnology during the second quarter worth $32,000. nVerses Capital LLC bought a new stake in shares of Vir Biotechnology in the 3rd quarter valued at about $56,000. Magnetar Financial LLC acquired a new stake in Vir Biotechnology in the 2nd quarter valued at about $95,000. Finally, Quest Partners LLC raised its stake in Vir Biotechnology by 142.1% in the second quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock valued at $113,000 after buying an additional 7,452 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a report on Friday, November 1st. Barclays reduced their target price on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday. Finally, HC Wainwright reissued a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a research note on Monday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $36.40.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).